Freeze-Dried Plasma Approved but NATO Makes 100K Units vs. WWII's 10M

In August 2024, the FDA granted emergency use authorization for octaplasLG Powder, a freeze-dried plasma product by Octapharma that can be stored at room temperature and reconstituted in the field. This is a breakthrough for combat casualty care because fresh frozen plasma requires cold-chain logistics that are extremely difficult to maintain on a contested battlefield. But the production capacity is negligible relative to wartime demand: NATO nations currently produce barely 100,000 units of freeze-dried plasma annually, compared to over 10 million dried plasma units produced by the Allies during World War II. Blood product logistics is already the most fragile link in the combat casualty care chain. Whole blood has a 21-day shelf life and must be refrigerated. The Armed Services Blood Program shifted production from packed red blood cells to low-titer whole blood (LTOWB) in 2023, reducing PRBC production by 30 units/week to increase LTOWB by 15 units/week -- a 2:1 conversion ratio that actually reduces total available units. In a large-scale combat operation with thousands of casualties, the 'walking blood bank' (drawing blood from fellow soldiers in the field) becomes the primary resupply mechanism, but it requires pre-screening, typing, and training that most conventional units do not routinely practice. The structural bottleneck is manufacturing economics. Freeze-dried plasma requires specialized lyophilization facilities that are expensive to build and operate. In peacetime, civilian hospitals use liquid plasma and have no demand for freeze-dried products, so there is no commercial market to drive production scale. Military demand alone cannot justify the capital investment in manufacturing capacity. The result is a product that everyone agrees is essential for the next war but that nobody is producing at scale -- a classic peacetime procurement failure where the urgency of wartime need is discounted against the cost of peacetime readiness.